(2R,3S)-3-Methyl-1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-2-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1-yl)-piperazine | 683211-05-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,3S)-3-Methyl-1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-2-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1-yl)-piperazine
• CAS: 683211-05-4
• 化学式: C₂₅H₃₂N₂O₆S
• 分子量: 488.605
• InChiKey: NAFMLCSQQXSAAP-DJGWLWDWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.66
• 重原子数：
  34.0
• 可旋转键数：
  6.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  86.33
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  (2R,3S)-3-Methyl-1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-2-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1-yl)-piperazine 在 三氟乙酸 作用下， 生成 (2R,3S)-3-Methyl-1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-piperazine-2-carboxylic acid
  参考文献：
  名称：

  Synthesis and biological activity of piperazine-Based dual MMP-13 and TNF-α converting enzyme inhibitors

  摘要：

  A series of novel MMP-13 and TNF-alpha converting enzyme inhibitors based on piperazine 2-hydroxamic acid scaffolds are described. The TACE, MMP-1 and MMP-13 activity of these inhibitors as well as the effect of substitution of the piperazine nitro-en and the P-1' benzyloxy tailpiece is discussed. Moderate in vivo activity is observed with several members of this group. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00666-8
• 作为产物：
  描述：

  在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 生成 (2R,3S)-3-Methyl-1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-2-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1-yl)-piperazine
  参考文献：
  名称：

  Synthesis and biological activity of piperazine-Based dual MMP-13 and TNF-α converting enzyme inhibitors

  摘要：

  A series of novel MMP-13 and TNF-alpha converting enzyme inhibitors based on piperazine 2-hydroxamic acid scaffolds are described. The TACE, MMP-1 and MMP-13 activity of these inhibitors as well as the effect of substitution of the piperazine nitro-en and the P-1' benzyloxy tailpiece is discussed. Moderate in vivo activity is observed with several members of this group. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00666-8